Kasikova, Lenka
Rakova, Jana
Hensler, Michal
Lanickova, Tereza
Tomankova, Jana
Pasulka, Josef http://orcid.org/0000-0001-6190-0465
Drozenova, Jana
Mojzisova, Katerina
Fialova, Anna http://orcid.org/0000-0003-1436-5142
Vosahlikova, Sarka
Laco, Jan
Ryska, Ales
Dundr, Pavel
Kocian, Roman
Brtnicky, Tomas http://orcid.org/0000-0002-6204-1903
Skapa, Petr
Capkova, Linda
Kovar, Marek http://orcid.org/0000-0002-6602-1678
Prochazka, Jan http://orcid.org/0000-0003-4675-8995
Praznovec, Ivan
Koblizek, Vladimir
Taskova, Alice
Tanaka, Hisashi http://orcid.org/0000-0001-9223-4186
Lischke, Robert
Mendez, Fernando Casas
Vachtenheim, Jiri Jr http://orcid.org/0000-0002-1468-4242
Heinzelmann-Schwarz, Viola
Jacob, Francis http://orcid.org/0000-0002-0446-1942
McNeish, Iain A. http://orcid.org/0000-0002-9387-7586
Halaska, Michal J.
Rob, Lukas
Cibula, David
Orsulic, Sandra http://orcid.org/0000-0001-5119-8721
Galluzzi, Lorenzo http://orcid.org/0000-0003-2257-8500
Spisek, Radek
Fucikova, Jitka http://orcid.org/0000-0002-8423-479X
Article History
Received: 29 September 2022
Accepted: 13 March 2024
First Online: 21 March 2024
Competing interests
: L.G. is/has been holding research contracts with Lytix Biopharma, Onxeo and Promontory, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Sotio, Promontory, Noxopharm and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. R.Sp. is minority shareholder of Sotio Biotech a.s. A.R. declare advisory services and invited lectures for Amgen, AstraZeneca, BMS, Eli-Lilly, Janssen-Cilag, MSD, Roche. All other authors have no conflicts to declare.